The transmission dynamics of Norovirus in England: a genotype-specific modelling study
Abstract
Background Norovirus is the leading cause of acute gastroenteritis cases in England and worldwide, with diverse co-circulating genotypes. Recent surveillance in England shows GII.17 surpassing GII.4 in prevalence among reported cases, and vaccine candidates targeting multiple genotypes are advancing. However, most transmission models still focus on single-strain dynamics, limiting their ability to assess the role of co-circulating strains on population burden. Methods We developed an age structured multistrain transmission model that integrates norovirus genotype diversity, waning immunity, and cross-protection within genogroups. We calibrate to case and genotyping surveillance time-series from UKHSA with community-wide age structured incidence estimates and cross-sectional seroprevalence among English children to capture the transmission dynamics of the main co-circulating Norovirus strains in England. Using a calibrated model, we examine the case of an emerging GII.4 variant under different scenarios of transmissibility. Results We found that on average the current GII.4 strain has an R0 of ~3.6. We estimate the average number of lifetime Norovirus-caused AGE cases per person to be between 3 and 4, with 60% of children in England experiencing at least one symptomatic episode by the age of four. Our inference analysis suggests that cross-protection within genogroups (between strains of the same genogroup, like GII.4 with other GII), is very limited at conferring protection.…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause.
Read the paper
Related studies
- Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations
- Evidence-based clinical practice guidelines for irritable bowel syndrome 2020
- Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial
- Gastrointestinal manifestations in COVID-19
- COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
- Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.